These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. European union regulatory developments for new vaccine adjuvants and delivery systems. Sesardic D; Dobbelaer R Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409 [TBL] [Abstract][Full Text] [Related]
4. Current status and future trends in vaccine regulation--USA. Falk LA; Ball LK Vaccine; 2001 Feb; 19(13-14):1567-72. PubMed ID: 11166876 [TBL] [Abstract][Full Text] [Related]
5. Current adjuvants and new perspectives in vaccine formulation. Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399 [TBL] [Abstract][Full Text] [Related]
6. Nonclinical safety assessment of vaccines and adjuvants. Wolf JJ; Kaplanski CV; Lebron JA Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119 [TBL] [Abstract][Full Text] [Related]
7. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products. Lucas-Samuel S; Ferry N; Trouvin JH Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213 [TBL] [Abstract][Full Text] [Related]
8. New vaccine technologies. Wood DJ Dev Biol (Basel); 2002; 111():285-90. PubMed ID: 12678251 [TBL] [Abstract][Full Text] [Related]
9. Overview of global regulatory toxicology requirements for vaccines and adjuvants. Sun Y; Gruber M; Matsumoto M J Pharmacol Toxicol Methods; 2012 Mar; 65(2):49-57. PubMed ID: 22326278 [TBL] [Abstract][Full Text] [Related]
10. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage. Kaurav M; Madan J; Sudheesh MS; Pandey RS Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S818-S831. PubMed ID: 30307332 [TBL] [Abstract][Full Text] [Related]
11. The path forward. De Gregorio E Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572 [TBL] [Abstract][Full Text] [Related]
12. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Garçon N; Segal L; Tavares F; Van Mechelen M Vaccine; 2011 Jun; 29(27):4453-9. PubMed ID: 21527299 [TBL] [Abstract][Full Text] [Related]
13. Cancer vaccine THERATOPE- Biomira. Adis International Ltd Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588 [TBL] [Abstract][Full Text] [Related]
14. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Brennan FR; Dougan G Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222 [TBL] [Abstract][Full Text] [Related]
15. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Black S Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015 [TBL] [Abstract][Full Text] [Related]
16. The path to a successful vaccine adjuvant--'the long and winding road'. O'Hagan DT; De Gregorio E Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916 [TBL] [Abstract][Full Text] [Related]
17. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Adis International Ltd Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591 [TBL] [Abstract][Full Text] [Related]
18. Mode of action of adjuvants: implications for vaccine safety and design. Mastelic B; Ahmed S; Egan WM; Del Giudice G; Golding H; Gust I; Neels P; Reed SG; Sheets RL; Siegrist CA; Lambert PH Biologicals; 2010 Sep; 38(5):594-601. PubMed ID: 20659806 [TBL] [Abstract][Full Text] [Related]
19. Safety assessment of adjuvanted vaccines: Methodological considerations. Tavares Da Silva F; Di Pasquale A; Yarzabal JP; Garçon N Hum Vaccin Immunother; 2015; 11(7):1814-24. PubMed ID: 26029975 [TBL] [Abstract][Full Text] [Related]